Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 October 2019Website:
http://www.aprea.comNext earnings report:
26 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 22:36:20 GMTDividend
Analysts recommendations
Institutional Ownership
APRE Latest News
After losing some value lately, a hammer chart pattern has been formed for Aprea Therapeutics (APRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will participate in two presentations at the Maxim Healthcare Virtual Summit, to take place October 15 to 17, 2024.
DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea's potential best in class WEE1 inhibitor.
Aprea Therapeutics, Inc. (APRE) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.87 per share a year ago.
Aprea Therapeutics, Inc. (APRE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
What type of business is Aprea Therapeutics?
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-cancer drugs that reactivate the mutant tumor suppressor protein p53. Its lead candidate product, APR-246, is a low molecular weight reactivator of p53 that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The company was founded in 2006 and is headquartered in Boston, Massachusetts.
What sector is Aprea Therapeutics in?
Aprea Therapeutics is in the Healthcare sector
What industry is Aprea Therapeutics in?
Aprea Therapeutics is in the Biotechnology industry
What country is Aprea Therapeutics from?
Aprea Therapeutics is headquartered in United States
When did Aprea Therapeutics go public?
Aprea Therapeutics initial public offering (IPO) was on 03 October 2019
What is Aprea Therapeutics website?
https://www.aprea.com
Is Aprea Therapeutics in the S&P 500?
No, Aprea Therapeutics is not included in the S&P 500 index
Is Aprea Therapeutics in the NASDAQ 100?
No, Aprea Therapeutics is not included in the NASDAQ 100 index
Is Aprea Therapeutics in the Dow Jones?
No, Aprea Therapeutics is not included in the Dow Jones index
When was Aprea Therapeutics the previous earnings report?
No data
When does Aprea Therapeutics earnings report?
The next expected earnings date for Aprea Therapeutics is 26 March 2025